Internal medicine

DO placements in 2024 NRMP Match reach all-time high

Retrieved on: 
Friday, March 15, 2024
Internal medicine, GME, SOAP, Psychiatry, PGY-1, DOS, Rehabilitation, General surgery, Student, MBA, Anesthesiology, Gynaecology, Pediatrics, Emergency medicine, American Osteopathic Association, AOA, Obstetrics, NRMP, Medicine

CHICAGO, March 15, 2024 /PRNewswire/ -- The American Osteopathic Association is pleased to announce that a record high number of 7,705 osteopathic medical students and past DO graduates matched into year 1 (PGY-1) residency positions through the National Resident Matching Program (NRMP). This number reflects a 92.3% match rate for the 8,033 DO seniors who participated, a 0.7% increase from last year.

Key Points: 
  • This number reflects a 92.3% match rate for the 8,033 DO seniors who participated, a 0.7% increase from last year.
  • According to NRMP, the match rate for fourth-year osteopathic medical students has increased by 4.2 percentage points since 2019.
  • In total, the 2024 NRMP match included 6,395 certified programs offering 41,503 PGY-1 and PGY-2 training positions, the largest number in the NRMP's 72-year history.
  • The following breakdown shows the top 15 specialties matched into by fourth-year osteopathic medical students seeking PGY-1 placements:

Kaiser Permanente Bernard J. Tyson School of Medicine Announces Residency Placements of Inaugural Medical School Class

Retrieved on: 
Friday, March 15, 2024
Health, Internal medicine, Patient, Family medicine, Emergency medicine, University of Washington, University, Doctor of Philosophy, Faculty, MD, Student, Curriculum, Workforce, Kaiser Permanente, Work, Physician, HSS, Pediatrics, Nursing

PASADENA, Calif., March 15, 2024 /PRNewswire/ -- The Kaiser Permanente Bernard J. Tyson School of Medicine (KPSOM) celebrated its first annual Match Day, a milestone event for the new medical school and its inaugural class of students. On Match Day, medical students learn where they will begin their careers as physicians.

Key Points: 
  • PASADENA, Calif., March 15, 2024 /PRNewswire/ -- The Kaiser Permanente Bernard J. Tyson School of Medicine (KPSOM) celebrated its first annual Match Day, a milestone event for the new medical school and its inaugural class of students.
  • "KPSOM's inaugural class is a group of passionate, caring and creative students whose years of hard work have now led them to the threshold of residency," said Mark Schuster, MD, PhD, founding dean and chief executive officer of the Kaiser Permanente Bernard J. Tyson School of Medicine.
  • Internal Medicine, Emergency Medicine, and Family Medicine are the top three most matched specialty programs, and 38% are matched into primary care specialties, including Family Medicine, Internal Medicine, and Pediatrics.
  • "It has been an honor to support and watch this class grow, learn and thrive over the last four years," said Anne Eacker, MD, senior associate dean for student affairs at Kaiser Permanente Bernard J. Tyson School of Medicine.

NRMP® Celebrates Match Day for the 2024 Main Residency Match®, Releases Results for Over 44,000 Applicants and Almost 6,400 Residency Programs

Retrieved on: 
Friday, March 15, 2024
Interventional radiology, PGY-1, Internal medicine, Growth, Pathology, Med-Peds, COVID-19, Anne Ferguson-Smith, Internal, Emergency medicine, MD, MBA, Competition (economics), Cardiothoracic surgery, Orthopedic surgery, BSN, Acceptance, Workforce, Physician, Doctor of Health Science, NRMP, Nursing

This year's Match included 44,853 applicants who certified a rank order list ("active applicants") and 41,503 certified positions in 6,395 residency training programs.

Key Points: 
  • This year's Match included 44,853 applicants who certified a rank order list ("active applicants") and 41,503 certified positions in 6,395 residency training programs.
  • A total of 50,413 applicants registered in the 2024 Main Residency Match, an all-time high and increase of 2,257 or 4.7 percent over last year.
  • Increases afforded applicants access to 125 more programs and 1,128 positions which is 2.8 percent more than the 2023 Main Residency Match.
  • Detailed SOAP results will be available in the 2024 Main Residency Match Results and Data Book, which is published in the Spring.

The Inner Circle Dean acknowledged Dean M. Kirkel as a Distinguished Life Member

Retrieved on: 
Wednesday, March 13, 2024
Diagnosis, Principal, Internal medicine, Faculty, Coagulopathy, Mentorship, Lymphoma, Hematology, Immunotherapy, Disease, Physician, Alpha Omega Alpha, George Washington University, Education, Private practice, Patient, Research, Fellow, Cancer, University, American College, Society, Mary, mother of Jesus, Breast cancer, Pain management, Multimedia, Medical school, Inner circle, Nursing

MARIETTA, Ga., March 13, 2024 /PRNewswire/ -- Prominently featured in The Inner Circle, Dean M. Kirkel is acknowledged as a Distinguished Life Member for his contributions to the field of Oncology.

Key Points: 
  • MARIETTA, Ga., March 13, 2024 /PRNewswire/ -- Prominently featured in The Inner Circle, Dean M. Kirkel is acknowledged as a Distinguished Life Member for his contributions to the field of Oncology.
  • Dr. Kirkle pursued higher education at the University of Witwatersrand, Faculty of Medicine in South Africa where he earned a Medical Doctor degree.
  • He completed an internship and internal medicine residency at St. Mary's Hospital/St Louis University and finished a Fellowship in hematology and oncology at George Washington University.
  • He launched his career in private practice in Boynton Beach, FL, where he provided personalized care to patients battling cancer.

Cedar Health Research Launches Two New Clinical Research Sites in Texas

Retrieved on: 
Wednesday, March 13, 2024
United States Census Bureau, Health, Internal medicine, Neurology, DSM-IV codes, CHR, Partnership, Patient, Research, Clinical trial, Vaccine, Endocrinology, Women's health, Pharmaceutical industry

DALLAS, March 13, 2024 /PRNewswire/ -- Today, Cedar Health Research®, a multi-therapeutic independent clinical research site and patient network, officially announced two new sites in Texas located in Arlington, TX and Midland, TX.

Key Points: 
  • DALLAS, March 13, 2024 /PRNewswire/ -- Today, Cedar Health Research®, a multi-therapeutic independent clinical research site and patient network, officially announced two new sites in Texas located in Arlington, TX and Midland, TX.
  • Cedar Health Research expands independent clinical research site and patient network with Arlington and Midland sites.
  • The Arlington site will now serve as the Tarrant County mid-cities hub location for Cedar Health Research's (CHR) Dallas-Fort Worth clinical operations.
  • "When Cedar Health Research launched in 2020, we pursued the mission of expanding clinical trial access to the diverse communities of Texas through our unique technology enabled healthcare partnership model.

Study Links Key Gene to Protection from Severe Illness and Death From Covid Infections in Men Under Age 75

Retrieved on: 
Wednesday, March 13, 2024
Inflammation, Gene, Brain, Letter, Internal medicine, Rheumatoid arthritis, COVID-19, NYU Langone Health, Infection, Disease, Abramson, Risk, Patient, APG system, Journal, Research, IL1, Factorization of polynomials, Canakinumab, NYU, Death, Doctor of Philosophy, SARS-CoV-2, Attur, Salem, Arthritis, Woman, Male, MPH, National Institutes of Health, IL1RN, Vasopressin receptor 2, Bangladesh Technical Education Board, Fatigue, Blood, Viral, Hospital, Pharmaceutical industry

NEW YORK, March 13, 2024 /PRNewswire/ -- A certain variant of a key anti-inflammatory gene protects men under age 75 from severe illness and death when hospitalized from Covid-19, a genetic analysis of their blood shows.

Key Points: 
  • NEW YORK, March 13, 2024 /PRNewswire/ -- A certain variant of a key anti-inflammatory gene protects men under age 75 from severe illness and death when hospitalized from Covid-19, a genetic analysis of their blood shows.
  • According to the study authors, the protective gene in question, an interleukin-1 receptor antagonist (IL1RN) variant, appears to tamp down inflammation.
  • Overall, more men than women (240 men, at 60.5%; and 157 women, at 39.5%) died from their disease, with women 20% less likely to die than men.
  • Funding support for this study was provided by National Institutes of Health grants P30CA016087 and R21AR078466.

Aegis Living Appoints Renowned Pulmonary and Sleep Expert Dr. Raj Dasgupta as Chief Medical Officer

Retrieved on: 
Tuesday, March 12, 2024
Internal medicine, Health, Longevity, Thomas Jefferson University, Sleep hygiene, Associate, Philosophy, Aegis, Diabetes, Television, Medicine, FACP, Research, Sleep, CNN, Columbia University, University, USC, Quality of life, Jefferson Abington Hospital, News, Michigan State University, Cognitive behavioral therapy, Mount Sinai West, FCCP, Nursing care plan, CMO, Cure, ABC News, Dementia

BELLEVUE, Wash., March 12, 2024 /PRNewswire/ -- Aegis Living, a national leader in senior assisted living and memory care, has appointed Raj "Dr. Raj" Dasgupta MD, FACP, FCCP, FAASM, as Chief Medical Officer (CMO). Dr. Raj's appointment strengthens Aegis' healthcare expertise to further integrate wellness and longevity into the care of its residents, families and team members.

Key Points: 
  • BELLEVUE, Wash., March 12, 2024 /PRNewswire/ -- Aegis Living , a national leader in senior assisted living and memory care, has appointed Raj "Dr. Raj" Dasgupta MD, FACP, FCCP, FAASM, as Chief Medical Officer (CMO).
  • While one's lifespan defines how long they will live, healthspan is the quality of life that Aegis Living aims to impact.
  • While the primary beneficiaries will be Aegis Living residents and families, Aegis also aims to support and influence team members.
  • "I am honored to join the leadership team at Aegis Living to advance the level of care and wellness not yet experienced in senior living," said Dr. Raj.

Rochester Clinical Research Announces New Site in Buffalo, New York

Retrieved on: 
Tuesday, March 12, 2024
Internal medicine, RCR, CNS, Infection, Research, Site, Clinical trial, Running, Health, Gastroenterology, Pharmaceutical industry

ROCHESTER, N.Y., March 12, 2024 /PRNewswire/ -- Rochester Clinical Research ("RCR" or "the Company"), an Atlas Clinical Research Site, is excited to announce the expansion of its clinical research network with a new site set to open in Buffalo, New York.

Key Points: 
  • ROCHESTER, N.Y., March 12, 2024 /PRNewswire/ -- Rochester Clinical Research ("RCR" or "the Company"), an Atlas Clinical Research Site, is excited to announce the expansion of its clinical research network with a new site set to open in Buffalo, New York.
  • The new site, RCR Buffalo, is expected to commence operations in April of this year, marking a significant milestone in RCR's mission to advance medical research and patient care.
  • "We are proud to bring RCR's 30-year legacy of innovation and trusted clinical trials to Buffalo," said Kelley Powers, Head of Site at RCR.
  • RCR Buffalo invites interested participants to learn more about upcoming clinical research opportunities.

Rigel Pharmaceuticals Announces Appointment of Lisa Rojkjaer, M.D. as Chief Medical Officer

Retrieved on: 
Tuesday, March 12, 2024
CONNECT, Internal medicine, University, Growth, Biotechnology, Novo Nordisk, Hematology, Science, AML, Monroe Dunaway Anderson, Executive, Patient, SAN, Novartis, FLT3, Head, Drug, Therapy, Drug development, Sangamo Therapeutics, Molecular Partners, MorphoSys, Pharmaceutical industry

SOUTH SAN FRANCISCO, Calif., March 12, 2024 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced the appointment of Lisa Rojkjaer, M.D.

Key Points: 
  • SOUTH SAN FRANCISCO, Calif., March 12, 2024 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced the appointment of Lisa Rojkjaer, M.D.
  • as Executive Vice President and Chief Medical Officer.
  • Dr. Rojkjaer is an industry veteran with over 20 years of clinical development, regulatory, and medical affairs experience with a focus on hematology and oncology.
  • Prior to joining Rigel, Dr. Rojkjaer held several leadership positions in clinical development and medical affairs at biotechnology and global pharmaceutical companies, having most recently served as Chief Medical Officer of Sangamo Therapeutics.

Alcanza Clinical Research Appoints James Clark, M.D., as Chief Medical Officer

Retrieved on: 
Tuesday, March 12, 2024
ChromeOS, Internal medicine, Health equity, Research, Acquisition, University, Principal investigator, Multimedia, Medical device

LAKE MARY, Fla., March 12, 2024 /PRNewswire/ -- Alcanza Clinical Research , a mission-focused investigator site network, has appointed James Clark, M.D., as its first-ever Chief Medical Officer, marking a milestone in Alcanza's growth journey as it expands its network size and patient reach.

Key Points: 
  • LAKE MARY, Fla., March 12, 2024 /PRNewswire/ -- Alcanza Clinical Research , a mission-focused investigator site network, has appointed James Clark, M.D., as its first-ever Chief Medical Officer, marking a milestone in Alcanza's growth journey as it expands its network size and patient reach.
  • "We are thrilled to have Dr. Clark join the Alcanza senior leadership team as our Chief Medical Officer," said Bob Kinard, President and CEO, Alcanza.
  • "Now as Chief Medical Officer, I look forward to making a bigger impact toward our collective commitment to provide inclusive clinical research and accelerate the development of new therapies by reducing barriers to clinical research participation for all."
  • Alcanza is an integrated network of research facilities dedicated to reducing barriers to clinical research participation, especially in underrepresented patient populations.